International Journal of Cell Biology [47] H. R. Lee, J. M. Cho, D. H. Shin et al., “Adaptive response to GSH depletion and resistance to L-buthionine-(S,R)- sulfoximine: involvement of Nrf2 activation,” Molecular and Cellular Biochemistry, vol. 318, no. 1-2, pp. 23–31, 2008. [48] M. Loignon, W. Miao, L. Hu et al., “Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy,” Molecular Cancer Therapeutics, vol. 8, no. 8, pp. 2432–2440, 2009. [49] G. Eades, M. Yang, Y. Yao, Y. Zhang, and Q. Zhou, “miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells,” The Journal of Biological Chemistry, vol. 286, no. 47, pp. 40725–40733, 2011. [50] K. J. Hintze, K. A. Wald, H. Zeng, E. H. Jeﬀery, and J. W. Finley, “Thioredoxin reductase in human hepatoma cells is transcriptionally regulated by sulforaphane and other electrophiles via an antioxidant response element,” Journal of Nutrition, vol. 133, no. 9, pp. 2721–2727, 2003. [51] L. Campbell, F. Howie, J. R. Arthur, F. Nicol, and G. Beckett, “Selenium and sulforaphane modify the expression of selenoenzymes in the human endothelial cell line EAhy926 and protect cells from oxidative damage,” Nutrition, vol. 23, no. 2, pp. 138–144, 2007. [52] A. Banning, S. Deubel, D. Kluth, Z. Zhou, and R. Brigelius- Flohe´, “The GI-GPx gene is a target for Nrf2,” Molecular and Cellular Biology, vol. 25, no. 12, pp. 4914–4923, 2005. [53] A. Singh, T. Rangasamy, R. K. Thimmulappa et al., “Glu- tathione peroxidase 2, the major cigarette smoke-inducible isoform of GPX in lungs, is regulated by Nrf2,” American Journal of Respiratory Cell and Molecular Biology, vol. 35, no. 6, pp. 639–650, 2006. [54] S. Gromer, S. Urig, and K. Becker, “The thioredoxin system- from science to clinic,” Medicinal Research Reviews, vol. 24, no. 1, pp. 40–89, 2004. [55] E. S. J. Arne´r, “Focus on mammalian thioredoxin reductases— important selenoproteins with versatile functions,” Biochimica et Biophysica Acta, vol. 1790, no. 6, pp. 495–526, 2009. [56] A. Holmgren, “Thioredoxin,” The Annual Review of Biochem- istry, vol. 54, pp. 237–271, 1985. [57] M. Berggren, A. Gallegos, J. R. Gasdaska, P. Y. Gasdaska, J. Warneke, and G. Powis, “Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the eﬀects of serum stimulation and hypoxia,” Anticancer Research, vol. 16, no. 6, pp. 3459–3466, 1996. [58] H. Mo¨rk, B. Lex, M. Scheurlen et al., “Expression pattern of gastrointestinal selenoproteins—targets for selenium supple- mentation,” Nutrition and Cancer, vol. 32, no. 2, pp. 64–70, 1998. [59] G. F. Merrill, P. Dowell, and G. D. Pearson, “The human p53 negative regulatory domain mediates inhibition of reporter gene transactivation in yeast lacking thioredoxin reductase,” Cancer Research, vol. 59, no. 13, pp. 3175–3179, 1999. [60] P. J. Moos, K. Edes, P. Cassidy, E. Massuda, and F. A. Fitzpatrick, “Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia- inducible factor by impairing the selenoprotein thioredoxin reductase,” The Journal of Biological Chemistry, vol. 278, no. 2, pp. 745–750, 2003. [61] A. Sakurai, M. Nishimoto, S. Himeno et al., “Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role of NF-E2-related factor-2,” Journal of Cellular Physiology, vol. 203, no. 3, pp. 529–537, 2005. 7 [62] J. Zhang, V. Sˇvehl´ıkova´, Y. Bao, A. F. Howie, G. J. Beckett, and G. Williamson, “Synergy between sulforaphane and selenium in the induction of thioredoxin reductase 1 requires both transcriptional and translational modulation,” Carcinogenesis, vol. 24, no. 3, pp. 497–503, 2003. [63] E. S. J. Arne´r and A. Holmgren, “The thioredoxin system in cancer,” Seminars in Cancer Biology, vol. 16, no. 6, pp. 420– 426, 2006. [64] L. Gan, X. L. Yang, Q. Liu, and H. B. Xu, “Inhibitory eﬀects of thioredoxin reductase antisense RNA on the growth of human hepatocellular carcinoma cells,” Journal of Cellular Biochemistry, vol. 96, no. 3, pp. 653–664, 2005. [65] M. H. Yoo, X. M. Xu, B. A. Carlson, V. N. Gladyshev, and D. L. Hatﬁeld, “Thioredoxin reductase 1 deﬁciency reverses tumor phenotype and tumorigenicity of lung carcinoma cells,” The Journal of Biological Chemistry, vol. 281, no. 19, pp. 13005– 13008, 2006. [66] M. H. Yoo, X. M. Xu, B. A. Carlson, A. D. Patterson, V. N. Gladyshev, and D. L. Hatﬁeld, “Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-suﬃcient growth and DNA replication,” PLoS One, vol. 2, no. 10, Article ID e1112, 2007. [67] S. Ueda, H. Masutani, H. Nakamura, T. Tanaka, M. Ueno, and J. Yodoi, “Redox control of cell death,” Antioxidants and Redox Signaling, vol. 4, no. 3, pp. 405–414, 2002. [68] K. Becker, S. Gromer, R. Heiner Schirmer, and S. M u¨ller, “Thioredoxin reductase as a pathophysiological factor and drug target,” European Journal of Biochemistry, vol. 267, no. 20, pp. 6118–6125, 2000. [69] S. Urig and K. Becker, “On the potential of thioredoxin reductase inhibitors for cancer therapy,” Seminars in Cancer Biology, vol. 16, no. 6, pp. 452–465, 2006. [70] M. F. Rollins, D. M. Van Der Heide, C. M. Weisend et al., “Hepatocytes lacking thioredoxin reductase 1 have normal replicative potential during development and regeneration,” Journal of Cell Science, vol. 123, no. 14, pp. 2402–2412, 2010. [71] J. R. Prigge, S. Eriksson, S. V. Iverson et al., “Hepatocyte DNA replication in growing liver requires either glutathione or a single allele of txnrd1,” Free Radical Biology and Medicine, vol. 52, no. 4, pp. 803–810, 2012. [72] P. K. Mandal, M. Schneider, P. Ko¨lle et al., “Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmaco- logic glutathione deprivation,” Cancer Research, vol. 70, no. 22, pp. 9505–9514, 2010. [73] E. S. Suvorova, O. Lucas, C. M. Weisend et al., “Cytoprotective Nrf2 pathway is induced in chronically Txnrd 1-deﬁcient hepatocytes,” PLoS One, vol. 4, no. 7, Article ID e6158, 2009. [74] R. F. Burk, K. E. Hill, A. Nakayama et al., “Selenium deﬁciency activates mouse liver Nrf2-ARE but vitamin E deﬁciency does not,” Free Radical Biology and Medicine, vol. 44, no. 8, pp. 1617–1623, 2008. [75] M. M u¨ller, A. Banning, R. Brigelius-Flohe´, and A. Kipp, “Nrf2 target genes are induced under marginal selenium-deﬁciency,” Genes and Nutrition, vol. 5, no. 4, pp. 297–307, 2010. [76] S. Fourquet, R. Guerois, D. Biard, and M. B. Toledano, “Activa- tion of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulﬁde formation,” The Journal of Biological Chemistry, vol. 285, no. 11, pp. 8463–8471, 2010. [77] F. F. Chu, J. H. Doroshow, and R. S. Esworthy, “Expression, characterization, and tissue distribution of a new cellular selenium-dependent glutathione peroxidase, GSHPx-GI,” The Journal of Biological Chemistry, vol. 268, no. 4, pp. 2571–2576, 1993.